ClinicalTrials.gg
RecruitingNCT07569783Updated Sep 17, 2026

tDCS for Reducing the Incidence of OEI After Cesarean Section

An interventional study of Transcranial direct current stimulation and Transcranial direct current stimulation (placebo stimulation) in Itching Symptoms and Itching Caused by Epidural Use of Opioids, sponsored by Affiliated Hospital of Nantong University. Recruiting at 1 site in China. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by Affiliated Hospital of Nantong University · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 48 studies in Pruritus with a site in China — 18 open to participants now, 20 under way, 4 of them phase 3. Pruritus · China.

Planned enrollment
21st of 46
104 · median 92
Started
2026
with 10 others
No phase
19 of 48
8 open now
Primary completion
2026-12
later than 5 of 19 live
Registered
40th of 48
by date

Among the 48 studies in Pruritus with a site in China, this one is the 21st largest by planned enrollment of the 46 interventional ones that give a count, is one of 11 that started in 2026, is one of 19 with no phase, reaches primary completion later than 5 of the 19 other live ones, and was the 40th registered.

Pruritus

491 studies on the registry are indexed under Pruritus; 94 are open to participants now.

Browse Pruritus studies →

Open to participants now

18 of the 48 studies in Pruritus with a site in China are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 54 Pruritus studies recruiting now, 22 (41%) set no upper age limit and 24 (44%) stop at 75 or younger; 15 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Pruritus with a site in China, or all of them as a file.
02

Study summary

Cesarean section is the most common obstetric surgery worldwide. Epidural anesthesia has become the preferred anesthesia method for cesarean sections due to its definite analgesic effect and minimal impact on mother and baby. To ensure postoperative analgesia, intrathecal administration of morphine (the preferred opioid for obstetric intrathecal analgesia) is a routine clinical protocol, but morphine-induced postoperative pruritus is a common adverse reaction. A study targeting the cesarean section population confirmed that the incidence of pruritus after epidural morphine administration is as high as 40%-75%.Transcranial direct current stimulation (tDCS) can enhance the activity of GABAergic inhibitory interneurons in the spinal dorsal horn through the cortical-spinal descending pathway, reverse the inhibitory effect of morphine on them, and restore negative feedback regulation of itch-specific GRPR⁺ neurons; at the same time, it downregulates the phosphorylation level and membrane expression of μ-opioid receptors in the spinal dorsal horn, weakening the receptor activation efficiency of morphine. On the other hand, tDCS can reduce peripheral nerve excitability, decrease mast cell degranulation in the skin, and reduce the release of histamine and tryptase; simultaneously, it inhibits the activation of glial cells in the spinal cord/cortex, decreases the secretion of pro-inflammatory factors such as TNF-α and IL-6, and blocks the vicious cycle of 'inflammation-receptor upregulation-itch exacerbation,' thereby reducing the occurrence of itch.This study aims to explore the effect of transcranial direct current stimulation (tDCS) on the incidence of morphine-induced itching after cesarean section by inhibiting the central itch perception circuits in cesarean section patients and antagonizing the disinhibitory effects mediated by μ-opioid receptors in the spinal dorsal horn.

03

Conditions studied

  • Itching Symptoms
  • Itching Caused by Epidural Use of Opioids

Browse trials for

Keywords

  • Transcranial direct current stimulation
  • Opioid-induced Pruritus after Epidural Administration
  • Cesarean section
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-40 years, gestational age 37-41 weeks, singleton full-term pregnancy;
  • Planned elective or emergency cesarean section, using epidural anesthesia (0.1\~0.2 mg/kg of morphine administered intrathecally during surgery);
  • (ASA) classification I-III;
  • Conscious and able to cooperate to complete scale assessments, serum sample collection, and postoperative follow-up;
  • Voluntarily participate in the study and sign the form.

Exclusion criteria

Exclusion Criteria:

  • Presence of for tDCS (such as skull defects, intracranial metal implants, history of epilepsy, coagulation disorders);
  • Allergy to opioids or a history of severe OEI;
  • Presence of skin diseases (such as eczema, urticaria), liver diseases (cholestasis), mental disorders, or cognitive impairments;
  • Coexisting pregnancy complications (preeclampsia, gestational diabetes, diseases);
  • Use of medications within the past week that may affect itch assessment, such as antihistamines, 5-HT3 receptor antagonists, or anti-inflammatory drugs.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
104 participants (estimated)

Study arms

  • Sham comparator
    control group (sham stimulation group)

    Device: Transcranial direct current stimulation (placebo stimulation)

  • Experimental
    Case group (tDCS group)

    Device: Transcranial direct current stimulation

Interventions

  • DeviceTranscranial direct current stimulation

    Patients in the transcranial direct current stimulation (tDCS) group had the anode of the tDCS device placed on the left dorsolateral prefrontal cortex (F3 area) and the cathode on the right mastoid. The tDCS was administered on the day of surgery (starting within 5 minutes after delivery of the fetus and ending upon transfer to the PACU after surgery). The current intensity was 1.5 mA.

  • DeviceTranscranial direct current stimulation (placebo stimulation)

    Sham stimulation group (control group): The anode of the electrical stimulator is placed on the left dorsolateral prefrontal cortex (F3 region) and the cathode on the right mastoid area. A current of 1.5 mA is applied only during the first 30 seconds after the start of stimulation, after which the current is reduced to 0 mA. All other procedures (electrode placement, stimulation duration, intervention frequency) are the same as those in the experimental group.

06

What researchers measure

Primary outcomes

  1. Incidence of itching within 24 hours after surgery (defined as VAS itching score ≥1)

    The VAS scoring standard for the degree of itching is a tool used to assess the severity of itching. VAS stands for Visual Analog Scale. The following are the standards for VAS scoring of itching severity: 0 points: No itching. 1-3 points: Mild itching, does not affect daily life. 4-6 points: Moderate itching, somewhat affects daily life. 7-9 points: Severe itching, seriously affects daily life, requires active treatment. 10 points: Extremely severe itching, unbearable, requires immediate treatment.

    Time frame: 24 hours after surgery

Secondary outcomes

  1. Incidence of itching at 12 and 48 hours postoperatively; VAS scores for itching at each time point; duration of itching and time of peak appearance

    Time frame: 12 hours post-operation and 48 hours post-operation

  2. Number of times the analgesic pump was pressed and the doses of additional morphine within 48 hours postoperatively; VAS pain scores at 12, 24, and 48 hours postoperatively

    Time frame: 12 hours, 24 hours, and 48 hours after surgery

  3. Maternal adverse reactions (nausea and vomiting, drowsiness, dizziness, ear pain, skin erythema) incidence; neonatal 1-minute and 5-minute Apgar scores, birth weight, complications within 72 hours (jaundice, shortness of breath, feeding difficulties)

    Time frame: Within 72 hours after surgery

  4. Preoperative and postoperative 24h serum histaminelevels

    Time frame: 24 hours before surgery and 24 hours after surgery

  5. Preoperative and postoperative 24h trypsin-like enzymelevels

    Time frame: 24 hours before surgery and 24 hours after surgery

  6. Preoperative and postoperative 24h TNF-α levels

    Time frame: 24 hours before surgery and 24 hours after surgery

  7. Preoperative and postoperative 24h IL-6 levels

    Time frame: 24 hours before surgery and 24 hours after surgery

  8. Preoperative and postoperative 24h β-endorphin levels

    Time frame: 24 hours before surgery and 24 hours after surgery

  9. Preoperative and postoperative 24h gastrin-releasing peptide precursor (ProGRP) levels

    Time frame: 24 hours before surgery and 24 hours after surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Dec 2026, 7 months after the start.

Of 85 non-industry interventional studies with no phase under Pruritus, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 14. This study's planned 7 months is close to that.

Counting every sponsor, half of 101 studies reached it within 7 months; a quarter within 3 and three quarters within 13.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2026
First posted
May 6, 2026
StartActual
May 10, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Feb 20, 2027
Last update
Sep 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07569783
Lead sponsor
Affiliated Hospital of Nantong University
Responsible party
Chaochao Zhong (Chief Researcher, Affiliated Hospital of Nantong University) — Principal investigator
First posted
May 6, 2026
Start date
May 10, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Feb 20, 2027 (estimated)
Last update
Sep 17, 2026

Study contacts

Chao Chao Zhong, M.D.
Contact
zhong249767626@163.com
15152460489

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion